Aveo signs BI to manufacture PhII candidate ficlatuzumab
02 December 2011
Nancy Faigen
Please Login to read the full article.
02 December 2011
Nancy Faigen
nancy.faigen@informausa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Aveo licences preclinical RON-targeted antibodies to J&J, for $15 million up front
- Aveo raises another $100M, as tivozanib goes head-to-head with Nexavar in RCC
- AVEO/Astellas 2012 filing for tivozanib as it beats Nexavar in Ph III kidney cancer trial
- Pfizer's Torisel fails in Phase III second-line kidney cancer trial
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
EVENTS
Today
Le Plaza Hotel, Brussels, Belgium
Today
Diplomat Hotel, Prague, Czech Republic
Today
Business Design Centre, London
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
